Skip to main content
SpringerLink
Log in

Medullary Thyroid Cancer

  • Chapter
  • First Online:
Endocrine Surgery

Part of the book series: Springer Specialist Surgery Series ((SPECIALIST))

  • 1704 Accesses

First described in 1959, medullary thyroid cancer (MTC) currently accounts for 5–10% of all thyroid cancers. MTC consists of a spectrum of disease that ranges from an extremely indolent tumor that can go unchanged for years to an aggressive variant that is associated with a high mortality rate. The majority of MTC are sporadic, but up to 25% of MTC are due to a germline genetic mutation. Hereditary MTC can be seen in isolation [familial MTC (FMTC)] or as part of the multiple endocrine neoplasia syndrome type 2 (2A or 2B).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.

    Article  PubMed  Google Scholar 

  2. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92(2):450–5.

    Article  PubMed  CAS  Google Scholar 

  3. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90(4):2029–34.

    Article  PubMed  CAS  Google Scholar 

  4. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol. 2007;19(1):18–23.

    Article  PubMed  CAS  Google Scholar 

  5. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab. 2000;85(2):919–22.

    Article  PubMed  CAS  Google Scholar 

  6. Machens A, Dralle H. Pretargeted anti-carcinoembryonic-antigen radioimmunotherapy for medullary thyroid carcinoma. J Clin Oncol. 2006;24(20):e37; author reply e38.

    Article  PubMed  Google Scholar 

  7. de Groot JW, Kema IP, Breukelman H, et al. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid. 2006;16(11):1163–70.

    Article  PubMed  Google Scholar 

  8. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12):5658–71.

    Article  PubMed  CAS  Google Scholar 

  9. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005; 15(6):531–44.

    Article  PubMed  CAS  Google Scholar 

  10. Ogilvie JB, Kebebew E. Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J Natl Compr Canc Netw. 2006; 4(2):139–47.

    PubMed  Google Scholar 

  11. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see commetns]. Cancer. 1998; 83(12):2638–48.

    Article  PubMed  CAS  Google Scholar 

  12. Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, et al. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid. 2007; 17(6):549–56.

    Article  PubMed  Google Scholar 

  13. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996; 6(4):305–10.

    Article  PubMed  CAS  Google Scholar 

  14. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6077–84.

    Article  PubMed  CAS  Google Scholar 

  15. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353(11):1105–13.

    Article  PubMed  CAS  Google Scholar 

  16. Moley JF, Shervin, N. Medullary thyroid cancer. In Clark OH, Duh, Q.Y., and Kebebew, E, editors. Textbook of endocrine surgery, Vol. 2. Philadelphia, PA: Elsevier Inc., 2005. 129–141.

    Chapter  Google Scholar 

  17. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229(6):880–7; discussion 887–8.

    Article  PubMed  CAS  Google Scholar 

  18. Greenblatt DY, Elson D, Mack E, Chen H. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg. 2007;30(2):108–12.

    Article  PubMed  Google Scholar 

  19. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31(10):1960–5.

    Article  PubMed  Google Scholar 

  20. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88(5):2070–5.

    Article  PubMed  CAS  Google Scholar 

  21. Network NCC. Practice Guidelines for Thyroid Carcinoma: Medullary Carcinoma 2007.

    Google Scholar 

  22. Kebebew E, Greenspan FS, Clark OH, et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005;200(6):890–6.

    Article  PubMed  Google Scholar 

  23. Machens A, Hofmann C, Hauptmann S, Dralle H. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. Eur J Endocrinol. 2007;157(1):85–93.

    Article  PubMed  CAS  Google Scholar 

  24. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99(1):60–6.

    PubMed  CAS  Google Scholar 

  25. Moley JF, Wells SA, Dilley WG, Tisell LE. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery. 1993;114(6):1090–5; discussion 1095–6.

    PubMed  CAS  Google Scholar 

  26. Tung WS, Vesely TM, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery. 1995;118(6):1024–9; discussion 1029–30.

    Article  PubMed  CAS  Google Scholar 

  27. Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887–95.

    Article  PubMed  CAS  Google Scholar 

  28. Faik Erdogan M, Gursoy A, Erdogan G, Kamel N. Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun. 2006;27(4):359–62.

    Article  PubMed  CAS  Google Scholar 

  29. Martins RG, Rajendran JG, Capell P, et al. Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol. 2006;24(11):1653–5.

    Article  PubMed  Google Scholar 

  30. You YN, Lakhani V, Wells SA, Jr, Moley JF. Medullary thyroid cancer. Surg Oncol Clin N Am. 2006;15(3):639–60.

    Article  PubMed  Google Scholar 

  31. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007; 92(9):3466–9.

    Article  PubMed  Google Scholar 

  32. Wells SA, Jr, Gosnell JE, Gagel RF, Moley JF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol. 2007;25(18S):6018.

    Google Scholar 

  33. Sherman SI, Schlumberger, MJ, Droz J, Hoffman M, et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol. 2007;25(18S):6017.

    Google Scholar 

  34. Kober F, Hermann M., Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic thyroid cancer. J Clin Oncol. 2007;25(18S):14065.

    Google Scholar 

  35. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2005;289(4):G636–42.

    PubMed  CAS  Google Scholar 

  36. Kunnimalaiyaan M, Yan S, Wong F, et al. Hairy enhancer of split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery. 2005;138(6):1137–42; discussion 1142.

    Article  PubMed  Google Scholar 

  37. Kunnimalaiyaan M, Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs. 2006;17(2):139–42.

    Article  PubMed  CAS  Google Scholar 

  38. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid. 2005;15(6):511–21.

    Article  PubMed  CAS  Google Scholar 

  39. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery. 2003;134(6):866–71; discussion 871–3.

    Article  PubMed  Google Scholar 

  40. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab. 2005;90(7):4350–6.

    Article  PubMed  CAS  Google Scholar 

  41. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756–67.

    Article  PubMed  CAS  Google Scholar 

  42. Carson-Walter EB, Smith DP, Ponder BA, et al. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene. 1998;17(3):367–76.

    Article  PubMed  CAS  Google Scholar 

  43. Chen H, Carson-Walter EB, Baylin SB, et al. Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1. Surgery. 1996;120(2):168–72; discussion 173.

    Article  PubMed  CAS  Google Scholar 

  44. Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999;6(8):559–68.

    Article  PubMed  CAS  Google Scholar 

  45. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther. 2005;4(6):910–7.

    Article  PubMed  Google Scholar 

  46. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517–25.

    Article  PubMed  CAS  Google Scholar 

  47. Machens A, Dralle H. DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer. Surgery. 2006;139(3):279–82.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Section of Endocrine Surgery, University of Wisconsin-Madison, Madison, WI, USA

    Rebecca S. Sippel MD

  2. Section of Endocrine Surgery Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA

    Herbert Chen MD

Authors
  1. Rebecca S. Sippel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom

    Johnathan Hubbard

  2. Coll Physicians & Surgeons Columbia, Fort Washington Avenue 161, New York, 10032, U.S.A.

    William B. Inabnet

  3. Queen Mary Hospital, University of Hong Kong Medical Centre, Pokfulam, Hong Kong, China, People's Republic

    Chung-Yau Lo

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Sippel, R.S., Chen, H. (2009). Medullary Thyroid Cancer. In: Hubbard, J., Inabnet, W., Lo, CY. (eds) Endocrine Surgery. Springer Specialist Surgery Series. Springer, London. https://doi.org/10.1007/978-1-84628-881-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-881-4_11

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-880-7

  • Online ISBN: 978-1-84628-881-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation